

Date: 26 June 2015

Resonance Health announces new clinical trial contract for FerriScan

The Board of Resonance Health today announced the signing of a two-year agreement with a pharmaceutical company, for the provision of FerriScan and cardiac T2* services in a phase II multi-centre study, for an undisclosed sum. Targeted to commence in the second half of 2015, the study will evaluate the efficacy and safety of a potential new treatment to address iron overload in patients with transfusion-dependent beta-thalassaemia.

Resonance Health will receive magnetic resonance image data from approximately 30 sites across the world. Using its patented and world-leading technology, changes to patients' liver iron concentration (LIC) will be evaluated at three stages during the trial. Assessment of cardiac iron loading will also be provided.

Resonance Health Executive Chairman, Dr Martin Blake commented "The award of this significant contract is a further endorsement of FerriScan's position as the gold standard in non-invasive measurement of liver iron concentration. It is widely used globally for accurate measurement of LIC in patients who are dependent upon regular blood transfusions in the treatment of a range of haemoglobinopathies and therefore accumulate excess iron which can ultimately be fatal."

"Pharmaceutical companies are constantly researching new and improved treatments for patients suffering from iron overload as a result of their inherited conditions and Resonance Health is delighted to be regarded as an essential partner in their efforts."

For further information contact:

Sander Bangma
Resonance Health
SanderB@resonancehealth.com

Adrian Bowers
Company Secretary
AdrianB@resonancehealth.com

P: +61 (0)8 9286 5300

W: www.resonancehealth.com

[Fact Sheet on Thalassaemia and Iron Overload](#)